Study: Pot not too hot for MS

Reprinted from PN/Paraplegia News October 2013

Synthetic Cannabis/marijuana derivative does not slow multiple sclerosis progression.

View Forum | Print Article | Font Size + / - | Back

A three-year trial shows dronabinol, a synthetic Cannabis/marijuana derivative, doesn’t slow multiple sclerosis (MS) progression.

The trial, conducted by John Zajicek, PhD, from Plymouth University Peninsula Schools of Medicine and Dentistry and his colleagues in the United Kingdom, found dronabinol couldn’t stop MS progression or brain atrophy and didn’t affect the occurrence of new areas of disease activity in the brain.

The cannabinoid use in progressive inflammatory brain disease (CUPID) trial involved 498 people with primary or secondary-progressive MS. Participants had varying degrees of gait impairment and other symptoms. Two-thirds were administered oral dronabinol and one-third took an inactive placebo for three years.

Based on previous lab studies, these types of cannabinoids may protect against the nervous system.

Results were published in the September issue of The Lancet Neurology.

To read the full study, visit


To order the October 2013 PN, Click Here.
To Subscribe, Click Here.

Article Forum

PN Forum discussions are intended to provide a place for free-flowing exchange of information, opinions, and comments and are designed to provide an enjoyable and informative expression for all participants.
Please review our Forum Rules for complete details.

Login with username and password (Forgot Password?)
New Post

Study: Pot not too hot for MS


Be the first to comment on this article.
(Register or login to add comments.)